Oral Presentation Australian Diabetes Society and the Australian Diabetes Educators Association Annual Scientific Meeting 2017

Insulin degludec (IDeg) is a basal insulin with a long and stable glucose-lowering effect and low day-to-day intra-patient variability compared with insulin glargine U100 (IGlar). This meta-analysis investigated the proportion of patients meeting the laboratory-measured FPG target of <7.2 mmol/L, defined as the upper limit of the recommended pre-meal plasma glucose goal based on the 2015 ADA Standards of Medical Care in Diabetes, at each visit during the maintenance period, as well as doing so without experiencing nocturnal hypoglycaemia. The maintenance period is defined as all visits from week 16 onwards. Nocturnal hypoglycaemia was defined as any confirmed (blood glucose <3.1 mmol/L) self-monitored event occurring between 00:01 and 05:59, inclusive. Patients (type 1 [T1D] or type 2 diabetes [T2D]) from seven open-label, randomised, treat-to-target trials treated with either IDeg (n=2501) or IGlar (n=1256) were included. Use of IDeg resulted in significantly more patients reaching the FPG target at each visit throughout the maintenance period, as well as doing so without experiencing nocturnal confirmed hypoglycaemia, compared with IGlar (Figure). These results were similar across the three patient populations; T1D, T2D insulin-treated and T2D insulin-naïve. In conclusion, more patients treated with IDeg can achieve target FPG without nocturnal confirmed hypoglycaemia compared with IGlar.

Figure: Odds ratios for patients meeting FPG target (<7.2 mmol/L) and without experiencing nocturnal hypoglycaemia.